|
KMID : 1148920130470040281
|
|
Nuclear Medicine and Molecular Imaging
2013 Volume.47 No. 4 p.281 ~ p.284
|
|
|
Radioimmunotherapy with 131I-Rituximab in a Patient with Diffuse Large B-Cell Lymphoma Relapsed After Treatment with 90Y-Ibritumomab Tiuxetan
|
|
Kang Geon-Wook
Kang Hye-Jin
Shin Dong-Yeop
Gu Ha-Ra
Choi Hong-Seok
Lim Sang-Moo
|
|
|
Abstract
|
|
|
|
We report a case that demonstrates the efficacy of radioimmunotherapy (RIT) with radioiodinated rituximab (131I-rituximab) for relapsed diffuse large B-cell lymphoma (DLBCL). A 79-year-old male patient with DLBCL initially achieved a complete response (CR) after six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) therapy. However, the lymphoma relapsed 20 months later. Although the patient had achieved a second and a third CR after two cycles of 90Y-ibritumomab tiuxetan, he experienced a third relapse approximately 3 years later. Between March and June 2011, the patient received three cycles of 131I-rituximab. Although he had achieved partial response after the second cycle, the disease progressed after the third cycle, and the total progression?free survival was thus 5 months. The patient suffered only relatively mild toxicity (grade 1 thrombocytopenia) during treatment. RIT with 131I-rituximab is therefore potentially effective in patients with relapsed DLBCL, even after the failure of 90Y-ibritumomab tiuxetan therapy.
|
|
|
KEYWORD
|
|
|
131I-rituximab, Rituximab, Radioimmunotherapy, Diffuse large B-cell lymphoma, Refractory
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|